ClinicalTrials.Veeva

Menu

Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin

University of Michigan logo

University of Michigan

Status

Enrolling

Conditions

Photoaging

Treatments

Device: Restylane-L
Device: Vehicle

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT06195605
HUM00230920

Details and patient eligibility

About

The purpose of the study is to investigate the impact of the injection of dermal filler on the quality of the skin dermal extracellular matrix in persons between the ages of 30-50 years. The quality of the dermal extracellular matrix will be assessed following injection of dermal filler compared to injection of saline vehicle.

Enrollment

15 estimated patients

Sex

All

Ages

30 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects must understand and sign the informed consent prior to participation
  • Subjects must be in generally good health
  • Subjects must be able and willing to comply with the requirements of the protocol

Exclusion criteria

  • Pregnant, plan to become pregnant during the study, or are nursing a child. Participants will be asked to self-report pregnancy

  • Individuals with bleeding disorders

  • Tend to heal poorly or form very thick scars called keloids

  • Have a lidocaine sensitivity, including those with epilepsy, impaired cardiac conduction, severely impaired hepatic function or severe renal dysfunction.

  • Individuals with active inflammation or infection of the skin, including active herpes infection.

  • Have a significant medical history or concurrent condition which the investigator(s) feel is not safe for study participation, including history of frequent herpes infections, and subjects planning to be exposed to excessive sun, Ultraviolet lamps and extreme cold weather during the first week after injection.

  • History of allergies to gram positive bacterial proteins

  • Individuals with who have undergone therapy with thrombolytics, anticoagulants, or inhibitors of platelet aggregation in the preceding 3 weeks.

  • Have an active inflammation or infection of the skin near the site of injection

  • Are taking any medications that suppress your immune system

  • Have severe allergies to medications or other things that we believe might make participation unsafe for you

  • Have a history of connective tissue diseases, such as:

    • rheumatoid arthritis
    • scleroderma
    • polymyositis/dermatomyositis
    • systemic lupus erythematosus (SLE)

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

15 participants in 1 patient group

Photodamaged skin
Experimental group
Treatment:
Device: Vehicle
Device: Restylane-L

Trial contacts and locations

1

Loading...

Central trial contact

Diane Fiolek

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems